MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Exclusion Criteria

• •1. Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment.
• •2. Prior receipt of any immune-related therapy
• •3. Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed.
• •4. Participants with a history of venous thrombosis within the past 3 months
• •5. Participants with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 3 months prior to start of treatment
• •6. Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment
• •7. Other invasive malignancy within 2 years
• •8. Any history of leptomeningeal disease or cord compression
• •9. Current or prior use of immunosuppressive medication within 14 days prior to the first dose.